The US Food and Drug Administration (FDA) has granted approval to AbbVie’s Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis (PsA) patients.

The indicated dosage is one 150mg subcutaneous dose of Skyrizi administered four times a year.

An inhibitor of interleukin-23 (IL-23), Skyrizi specifically hinders IL-23 by attaching to its p19 subunit.

Part of a partnership between Boehringer Ingelheim and AbbVie, Skyrizi is being developed and commercialised by AbbVie worldwide.

The latest approval is based on data from two Phase III randomised, multicentre, double-blind, placebo-controlled clinical trials, KEEPsAKE-1 and KEEPsAKE-2, which analysed the safety and efficacy of Skyrizi in adults with active PsA.

The trial included patients with inadequate response or not tolerant to biologic therapy and/or non-biologic disease-modifying antirheumatic drugs (DMARDs).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the trials, Skyrizi met the primary goal of ACR20 response at week 24 versus placebo and showed substantial enhancements across various other PsA manifestations, such as tender, swollen and painful joints.

Furthermore, at week 24¸ Skyrizi showed improvements in ACR50 and ACR70 responses versus placebo.

AbbVie research and development (R&D) senior vice-president and chief scientific officer Thomas Hudson said: “Patients often do not suspect a connection between their psoriasis skin symptoms and the joint pain, swelling and stiffness they may be experiencing, potentially leading to a delay in diagnosis and treatment of psoriatic arthritis. 

“We’re proud to expand the use of Skyrizi to patients with psoriatic arthritis who are living with the debilitating combination of skin and joint symptoms.”

In the US, Skyrizi is also approved for use in treating adults with moderate-to-severe plaque psoriasis, candidates for systemic therapy or phototherapy. 

Currently, Phase III trials of Skyrizi in Crohn’s disease, psoriasis, ulcerative colitis and psoriatic arthritis are underway.